Pages

▼
Showing posts with label ipilimumab. Show all posts
Showing posts with label ipilimumab. Show all posts
March 18, 2016

Things May Get Worse Before They Get Better, Unless They Get Better Right Away

›
On the blog's Current News page I wrote about the tumors of patients who received and responded to treatment with Amgen's talimoge...
August 15, 2015

Clinical & Business Value Proposition Pillar #5

›
Image source On Provectus' August 6th 2Q15 business update conference call , the company's COO/CFO Peter Culpepper introduced fi...
August 12, 2015

The Door

›
Image source Opaque as the Agency's process may appear to non-life sciences investors like me, and obviously highly generalized as m...
February 18, 2015

The Early Obsolescence of Checkpoint Inhibitors

›
Image source Take as a starting point Inman et al.’s 2007 article entitled Costimulation, coinhibition and cancer , and their statement...
January 18, 2015

Dr. Weber

›
An interview of Moffitt Cancer Center's Dr. Jeffrey Weber, M.D., Ph.D. by OncLive's Andrew Roth , Expert Discusses Integration of ...
June 10, 2014

“PV-10 might offer the perfect way to prime the immune system”

›
Two articles on PV-10, and Provectus and Moffitt ASCO 2014 posters came out today:  Provectus outlines path forward for PV-10 and  PV...
June 29, 2013

For $PVCT, it's the FDA's move

›
Just the weekend is left in the month of June. Saturdays and Sundays typically are historically low visitorship days for the blog. Yet, it...
May 25, 2013

@adamfeuerstein: What Wall Street's Watching at ASCO (The Burrill Report)

›
This podcast, featuring Adam Feuerstein, senior columnist for TheStreet.com, is worth hearing. Click on this link:  The Burrill Report (May ...
May 23, 2013

$PVCT's PV-10 Verified, Translated, Elucidated and Optimized by Moffitt

›
When Provectus issued a PR in January 2013 about Moffitt's Phase 1 feasibility study to elucidate PV-10's bystander effect, Moffi...
May 22, 2013

$PVCT: Bristol-Myers Visits The Blog, [Yet] Again

›
Bristol-Myers Europe (specifically, France) visited, looking at a blog post I had written about intralesionally-delivered local agents wi...
May 16, 2013

@Bloomberg @BloombergNews: Human Immune-Boosting Cancer Drugs Seen Extending Lives

›
An article by Robert Langreth here  (May 12, 2013). "Merck & Co. (MRK), Bristol-Myers Squibb Co. (BMY) and Roche Holding AG (ROG)...